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Background/purpose Intradermal vaccinations with
Bacillus Calmette-Guérin (BCG) give rise to a classic
primary complex that consists of a cutaneous nodule at the
site of injection and swelling of the regional lymph nodes.
This study was performed to evaluate the clinical course
of BCG lymphadenitis in relation to different management
strategies and to assess the microbial resistance to an
Indian BCG strain causing an Egyptian outbreak.
Patients and methods Prospective analytical follow-up
of 152 patients with BCG lymphadenitis attending the
Mansoura University Children Hospital between March
2010 and May 2011; of these, eight patients who had lymph
nodes that were B1 cm in size (group A = 5.3%) were
managed with regular follow-up, 86 patients who presented
with lymph nodes larger than 1–3 cm in size (group
B = 56.6%) received isoniazid and rifampicin for 6 months,
and 58 patients who presented with lymph nodes larger than
3 cm in size or with BCG abscess or sinus (group C = 38.1%)
were subjected to early surgical excision.
Results Of the 152 patients, the male-to-female ratio
was 1.7 : 1. The mean age was 5.97 months. The site of
the lesions was the left axilla (132 patients, 86.84%), left
supraclavicular (10 patients, 6.58%), cervical (four patients,
2.63%), and left axillary and supraclavicular (six patients,
3.95%). BCG lymphadenitis regressed spontaneously in
four patients of group A (50%), 24 patients of group B
showed an improvement in 6–9 months(27.9%), and
progressive enlargement (44 cases, 51.2%) and
development of BCG abscesses (18 cases, 20.9%)
occurred in the rest of the patients who needed surgical
treatment. For group C, surgical excision was performed
from the start. Pathological examination was performed
for all excised lymph nodes (124 patients, 81.6%) and
revealed granulomas with extensive caseation necrosis.
Microbiological examination was performed in all cases
and revealed acid fast bacilli in 100 samples (80.6%)
that were resistant to isoniazid, pyrazinamide, and
streptomycin but sensitive to rifampicin only in 25 samples.
Conclusion As antituberculous therapy was found to be
ineffective in the management of BCG lymphadenitis, we
recommend a careful choice of BCG vaccines to avoid
multidrug-resistant strains, early surgical excision of lymph
nodes larger than 3 cm and lymphadenopathy complicated
with abscess or sinus formation, and regular follow-up
of smaller lymph nodes. Ann Pediatr Surg 8:69–73
c 2012 Annals of Pediatric Surgery.
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Introduction
Mycobacterium bovis Bacillus Calmette-Guérin (BCG) vac-
cine is one of the most commonly administered vaccines
worldwide. It is a live-attenuated vaccine derived from
M. bovis, and for historical reasons, a number of genetically
different BCG vaccine strains are in use today [1,2]. It
is administered to all babies in Egypt within the first
40 days of life as a part of the global expanded program
of immunization recommended by the WHO [3].
Intradermal vaccinations with BCG give rise to a classic
primary complex that consists of a cutaneous nodule at the
site of injection and swelling of the regional lymph nodes.
This is usually self-limiting and requires no treatment [4].
Despite being considered a safe vaccine, complications
because of BCG vaccination can be classified into mild
and severe. Mild complications are usually localized, and
the most common complication is regional lymphadenitis.
Cutaneous complications, such as lupoid reaction and
eczema vaccinatum, form part of the mild spectrum of
complications. The incidence of mild complications
because of BCG is less than one per 1000 cases [5].
Severe complications caused by BCG are suppurative
lymphadenitis, osteitis/osteomyelitis, and disseminated
BCG infection. Their incidence rates are 100–1000 cases,
one to 700 cases, and two cases per 1 million vaccinations,
respectively [6].
The reported treatment of BCG lymphadenitis varies
from observation and follow-up to medical treatment or
surgical excision of the involved lymph nodes [7–9].
The influence of the particular BCG vaccine strain or
its susceptibility pattern to antituberculous drugs is not
considered when treating local adverse reactions and
disseminated BCG disease [10,11]. There are only
limited data on the susceptibility of BCG to different
antituberculous drugs and even less on the influence of
genetic differences between BCG vaccine strains on
susceptibility [12].
This study was conducted to evaluate the course of BCG
lymphadenitis occurring during an outbreak, which was
initiated because of a change from a Danish strain to an
Indian one, and its response to different management
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strategies as there are no clear data on the best treatment
of these infants.
Patients and methods
This study was a prospective analytic follow-up of 152
patients with BCG lymphadenitis attending Mansoura
University Children Hospital between March 2010 and
May 2011.They were assessed for age at presentation,
sex, place of vaccinations, site and size of lymphadenitis,
development of abscesses or discharging sinuses, micro-
biological and histopathological data, chest radiographs,
treatment, and outcome.
The criteria for the diagnosis of BCG lymphadenitis were
as follows:
(1) Isolated axillary, supraclavicular, or cervical lymph
node enlargement,
(2) history of BCG vaccination on the same side,
(3) absence of fever and other systemic symptoms [10].
According to the presenting features and sizes of the
lesions, the patients were categorized into three groups:
eight patients whose lymph nodes were B1 cm in size
(group A, 5.3%) were managed by regular follow-up, 86
patients who presented with lymph nodes larger than
1–3 cm in size (group B, 56.6%) received isoniazid and
rifampicin for 6 months, and 58 patients (group C, 38.1%)
who presented with lymph nodes larger than 3 cm in size
(38 cases) or presented with BCG abscess (16 cases) or
sinus (four cases) were subjected to early surgical
excision. Thus, group B was the only group that received
antituberculous drugs.
Surgical technique
The cases were preoperatively prepared with a 10-day
course of macrolides to decrease inflammation and
facilitate surgical dissection. Surgery was performed
under general anesthesia. The arm was abducted to
expose the lesion (Fig. 1) An axillary or a supraclavicular
skin crease incision was performed. This incision was
substituted with an elliptical skin incision when the
lesion was attached to the skin. The mass with the
surrounding tissues and other enlarged lymph nodes were
dissected and excised without injury to the axillary
structures (Fig. 2). The abscess (Fig. 3) was similarly
managed after drainage of the necrotic material. Tuber-
culous sinus, when present, was circumscribed and
excised with the underlying lymph nodes. Then, the
wound was irrigated with saline and a penrose drain was
inserted. The wound was closed with 4/0 polygalactin
sutures. Macrolides were administered for the first 10
postoperative days [8,13,14]. The drain and the sutures
were removed 7 days after the operation. During the
postoperative follow-up (4–6 months) period, the opera-
tive site was observed for the development of abscesses,
sinuses, or lymph nodes.
The excised mass was preserved in saline 0.9% and
processed for culture and Ziehl–Neelsen stain of
mycobacteria using standard procedures in multiple
media. The deposit of the ground homogenized specimen
was decontaminated with H2SO4 5%, neutralized with
distilled water, and inoculated onto two sets of four
media, that is Lowenstein–Jensen (LJ), LJ with sodium
pyruvate 0.5% (LJ-P), and selective mycobacterial growth
indicator tubes as indicated by the supplier (Becton and
Fig. 1
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Dickinson Franklin Lakes, NJ, USA) and examined every
week for any visible growth. Subcultures were prepared at
the end of the sixth week or when any growth was observed.
Cultures were identified on the basis of the results from the
niacin and thermo stable catalase tests and growth on LJ
medium containing para-nitrobenzoic acid [15].
Results
Of the 152 patients included, 96 were males and 56 were
females (1.7 : 1) and the mean age was 5.97 months
(range 2 months to 2 years) (Table 1). The age
distribution for each group is presented in (Table 2).
The site of the lesions was the left axilla in 132 patients
(86.84%), the left supraclavicular in 10 patients (6.58%),
cervical in four patients (2.63%), and left axillary and
supraclavicular in six patients (3.95%) (Table 3). An
enlarged noninflamed mass was the most common
presentation (94 patients, 61.84%) (Table 4).
BCG lymphadenitis regressed spontaneously in four
patients of group A (50%), whereas the other four
patients showed progressive enlargement of their lymph
nodes and developed abscesses that were surgically
excised. Twenty-four patients in group B showed an
improvement over a period of 6–9 months (27.9%),
whereas progressive enlargement (44 cases, 51.2%) and
development of BCG abscesses (18 cases, 20.9%)
occurred in the rest of the patients who needed surgical
treatment. For group C, surgical excision was performed
from the start (Table 5).
Pathological examination was performed for all excised
lymph nodes (124 cases, 81.6%) and revealed granulomas
with extensive caseation necrosis. Microbiological exam-
ination was performed in all cases and revealed acid fast
bacilli in 100 samples (80.6%) that were resistant to INH,
pyrazinamide, and streptomycin, but sensitive to rifam-
picin only in 25 samples (25%); resistance to the four
drugs was found in 75 samples (75%) as shown in culture
and sensitivity testing (Fig. 4).
From Table 5, we can see that surgical interference was
performed for 124 cases (81.6%) (58 in group C and 66 of
the complicated cases in groups A and B). No intrao-
perative complications were reported despite the pre-
sence of residual tissue edema and inflammation during
surgical dissection; this may be attributed to the super-
ficiality of the lesion under the skin.
The postoperative follow-up period was 4–6 months for
the cases that were subjected to surgery (124 patients).
During this period, three cases developed abscesses
formation and one case developed recurrent sinus. These
cases (3.2%) were reoperated on, without further
recurrence. Pathological examination of the four speci-
mens revealed tuberculous lesions.
Discussion
The BCG vaccine is a live-attenuated vaccine that is
generally well tolerated and free from severe adverse
reactions. In immunocompetent individuals, local adverse
reactions such as injection site abscess and lymphadenitis
occur in less than 1% of vaccinations [16]. However,
complications of the BCG vaccine have been well
documented. They typically occur when the vaccine
strains are changed or, less frequently, when there is an
error in manufacture, storage, or administration.
The Pediatric Surgery Department at Red Cross Chil-
dren’s Hospital has observed a significant increase in the
number of complications since 2000. The complications
were initially minor and attributed to the change in the
vaccine strain in that same year [17]; similarly, in our
series, we have observed an increase in complicated cases
referred to our hospital from different localities after the
change from the Danish vaccine to the Indian BCG one
(Indian Serum Institute Ltd, Pune, India).
Analysis of all epidemics has revealed that BCG
lymphadenitis is an exaggerated response to a more
immunogenic strain that was introduced in the immuni-
zation schedule [18–20]; this could explain this outbreak
of BCG lymphadenitis with the introduction of a new
BCG vaccine strain.











Table 2 Age distribution of the affected groups
Age (months) Group A Group B Group C
2–6 6 42 50
6–12 1 37 8
12–24 1 7 –
Table 3 Distribution of the involved lymph node groups in the
studied patients
Involved lymph nodes groups N (%)
Left axillary 132 (86.84)
Left supraclavicular 10 (6.58)
Cervical 4 (2.63)
Left axillary and supraclavicular 6 (3.95)
Total 152 (100)
Table 4 Description of involved lymph nodes at the time of
presentation
Lymph node state Number %
Only enlarged mass 94 61.84
A = 6 B = 56 C = 32 A = 6.4 B = 59.6 C = 34
Inflamed mass 38 25
A = 2 B = 30 C = 6 A = 5.3 B = 78.9 C = 15.8
Abscess 16 10.53
A = 0 B = 0 C = 16 A = 0 B = 0 C = 100
Sinus 4 2.63
A = 0 B = 0 C = 4 A = 0 B = 0 C = 100
Total 152 100
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Study was carried out to evaluate the course of BCG
lymphadenitis occurring during this outbreak and its
response to different management strategies as there are
no clear evidence-based data for the best treatment of
these infants.
BCG lymphadenitis presented at the age of 2–6 months
in 64.47% of our patients, although there can be a delay
up to 24 months, as found in this study, and the same has
been reported by Barouni et al. [21]. Several factors such
as age of the child, technique of vaccination, the BCG
strain, and the dose, potency, viability, and immunogeni-
city of the vaccine are implicated in the pathogenesis of
lymphadenitis [20].
On reviewing the literature, we found that there are
different management strategies for BCG lymphadenitis
as in the study by Goraya and Virdi [10], who
recommended expectant follow-up for nonsuppurative
BCG lymphadenopathy, but we observed that only four
out of eight patients (group A) who were managed only
by regular follow-up showed an improvement, whereas
the other four patients were managed surgically.
Other interventions have been used including systemic
isoniazid or systemic erythromycin [6]. Responses to 1-
month courses of treatment with isoniazid and erythro-
mycin were similar [7]. In 2000, Mark Fitzgerald [22]
reported that there was no difference between infants
treated with erythromycin, isoniazid, and a combination
of isoniazid and rifampicin as rapid development of
lymphadenopathy associated with a higher incidence of
suppuration and spontaneous drainage was observed
irrespective of medical therapy. Similarly, in our study,
only 24 patients out of 86 patients (group B) showed an
improvement on antituberculous therapy (27.9%). The
rest of the group was managed surgically.
At the time of presentation, patients of group C had
either lymph node abscesses (16 patients), sinuses (four
patients), or inflamed enlarged lymph nodes approxi-
mately 3 cm in size (38 patients); in addition, 62 patients
of group B developed the same complications of either
abscesses (18 patients) or progressive inflammation and
enlargement of the lymph nodes (44 patients). In
agreement with our results, Bolger et al. [20] reported,
in a retrospective study of 58 patients referred to their
hospital with BCG lymphadenopathy, that 32 patients
developed suppurative adenitis, 17 developed inoculation
site abscess, three patients had both inoculation site
abscess and suppurative adenitis, and only six had
nonsuppurative adenopathy.
Surgical excision of the involved lymph nodes was found
to be yield the best results according to Merry and
Fitzgerald [23] in a review study that included all cases
referred to the pediatric surgical clinic with BCG
lymphadenitis over an 11-year period; their results were
in agreement with Bhandari et al. [24], Hengster et al. [19]
and also with the results of our series.
Nazir and Qazi [4] reported that out of 60 children who
presented with BCG lymphadenitis, 52 who presented
with large (B3 cm) fluctuant lymph nodes required a
surgical procedure to avoid spontaneous rupture and sinus
formation. In our study, 81.6% of our cases finally
required a surgical intervention. However, Goraya and
Virdi [10] recommended needle aspiration of suppurative
BCG lymphadenitis and surgical excision was meant only
for cases of failed needle aspiration or for draining BCG
nodes. Similarly, Abdulhamed and Hummaida [25] found
a 92% success rate with needle aspiration and intake of
erythromycin for 4–6 weeks. Also, Paramasivan et al. [15]
showed no clear benefit of any particular surgical
intervention. Their studies question the role of a surgical
intervention at all; moreover, complete lymphadenect-
omy in the acute setting is not a viable option because of
a lack of any discernible dissection plane and the risk of
damaging vital axillary structures in the presence of an
inflamed and distorted anatomy. In our study, and to avoid
these surgical catastrophes, the affected child received
macrolides 10 days before surgical excision to decrease
tissue edema and inflammation and facilitate easy and
safe surgical dissection. No intraoperative complications
occurred in the operated cases, with an uneventful
postoperative course; this may be attributed to the
superficiality of the lesion under the skin.
Cultures of excised lymph nodes revealed resistance to
isoniazid, pyrazinamide, and streptomycin; however, sensi-
tivity to rifampicin was reported in 25 samples, which could
explain the poor response to antituberculous drugs in 62
patients of group B, whereas an improvement was reported
in 24 patients. Thus, we were dealing with a multidrug-
resistant strain of the BCG vaccine when compared with
other strains that were multidrug sensitive such as BCG-
Bulgaria (SL 222 Sofia), BCG-Connaught, BCG-Denmark
Table 5 The course of Bacillus Calmette-Guérin lymphadenitis in




Complicated by significant inflammation or
abscess
Group A (8) 4 (50%) 4 (50%)
Group B (86) 24 (27.9%) 62 (72.1%)
Group C (58) 0 (0%) 58 (100%)
Total 28 124
Fig. 4
Results of sensitivity testing for lymph node samples that yielded
mycobacterium tuberculous complex cultures.
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(SSI 1331), BCG-Japan (Tokyo 17‘2), and BCG-Medac
(RIVM from 1173-P2). As in our series, Ritz et al. [12] and
Barouni et al. [21] reported that a multidrug-resistant
mycobacterial strain was isolated from a 24-month-old child
with BCG lymphadenopathy who had received the
Brazilian BCG strain.
Conclusion
As antituberculous therapy has been found to be
ineffective in the management of BCG lymphadenitis
and resistance to isoniazid, rifampicin, pyrazinamide, and
streptomycin was detected, we recommend the careful
choice of BCG vaccines (to be of appropriate reactogeni-
city) to avoid multidrug-resistant strains, early surgical
excision of lymph nodes larger than 3 cm in size and
lymphadenopathy complicated with abscess or sinus
formation, and regular follow-up of smaller lymph nodes.
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